Advertisement

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

Christine P. Hans, Dennis D. Weisenburger, Timothy C. Greiner, Randy D. Gascoyne, Jan Delabie, German Ott, H. Konrad Müller-Hermelink, Elias Campo, Rita M. Braziel, Elaine S. Jaffe, Zenggang Pan, Pedro Farinha, Lynette M. Smith, Brunangelo Falini, Alison H. Banham, Andreas Rosenwald, Louis M. Staudt, Joseph M. Connors, James O. Armitage and Wing C. Chan

Article Figures & Data

Figures

Tables

  • Table 1.

    Antibodies used for immunohistochemical stains

    AntibodyCloneSourceAntigen retrievalDilution
    CD20 L26 Dako, Carpinteria, CA Citrate 30 1:200
    CD10 56C6 Ventana, Tucson, AZ Citrate 60 1:1
    Bcl-6 Polyclonal Santa Cruz Biotechnology, Santa Cruz, CA EDTA 60 1:75
    MUM1 MUM1p* Falini et al46 EDTA 30 1:10
    Bcl-2 124 Dako EDTA 30 1:10
    Cyclin D2 Polyclonal Santa Cruz Biotechnology EDTA 30 1:500
    FOXP1 JC12 Banham et al66 EDTA 30 1:80
    • Citrate 30 indicates 30 minutes at 95°C in citrate (10 mM, pH 6.0); citrate 60 indicates 60 minutes at 95°C in citrate (10 mM, pH 6.0); EDTA 30 indicates 30 minutes at 95°C in EDTA (ethylenediaminetetraacetic acid; 1 mM, pH 8.0), EDTA 60 indicates 60 minutes at 95°C in EDTA (1 mM, pH 8.0).

    • * This clone is now commercially available from Dako.

  • Table 2.

    Immunohistochemical stain results, TMA subclassification, IPI scores, and their effect on (OS) and EFS by univariate analysis

    No. (%)5-y OS, % (95% CI)P*5-y EFS, % (95% CI)P*
    CD10
        Negative 110 (72) 44 (34-53) .019 47 (37-57) .89
        Positive 42 (28) 74 (60-87) 51 (35-68)
    Bcl-6
        Negative 67 (44) 30 (18-42) < .001 35 (22-49) .013
        Positive 85 (56) 69 (59-79) 57 (46-68)
    MUM1
        Negative 80 (53) 66 (55-76) .009 62 (51-74) .003
        Positive 71 (47) 36 (24-48) 31 (19-43)
    Cyclin D2
        Negative 133 (87) 58 (45-71) < .001 54 (44-63) < .001
        Positive 19 (13) 11 (0-26) 7 (0-20)
    Bcl-2
        Negative 76 (50) 55 (43-66) .17 54 (42-67) .17
        Positive 76 (50) 50 (38-61) 42 (30-55)
    FOXP1
        Negative 57 (39) 58 (45-71) .29 52 (38-66) .25
        Positive 90 (61) 50 (39-61) 48 (36-59)
    TMA
        GCB 64 (42) 76 (66-87) < .001 63 (50-76) .007
        Non-GCB 88 (58) 34 (24-45) 36 (25-47)
    IPI score
        0-2 84 (66) 68 (58-78) < .001 65 (54-76) < .001
        3-5 44 (34) 31 (17-45) 23 (9-37)
    • * P values were determined by comparing survival distributions using the log-rank test.

  • Table 3.

    Clinical features of the 2 TMA subtypes of DLBCL

    Total (%)GCB (%)Non-GCB (%)P
    Total no. 152 64 88
    Sex
        Male 82 (54) 29 (45) 53 (60) .11
        Female 70 (46) 35 (55) 35 (40)
    Age, y
        Median 63 60 64 .56
        Range 14-90 14-82 21-90
    Stage
        I/II 77 (51) 32 (51) 45 (51) .97
        III/IV 74 (49) 31 (49) 43 (49)
    Extranodal sites
        Fewer than 2 120 (82) 48 (77) 72 (85) .36
        2 or more 27 (18) 14 (23) 13 (15)
    Karnofsky score
        Higher than 70 117 (77) 51 (80) 66 (76) .51
        70 or lower 34 (23) 13 (20) 21 (24)
    LDH
        Normal 65 (48) 32 (56) 33 (42) .11
        High 70 (52) 25 (44) 45 (58)
    IPI risk group
        Low, 0-2 84 (66) 35 (65) 49 (66) .80
        High, 3-5 44 (34) 19 (35) 25 (34)
    • LDH indicates lactate dehydrogenase.